Increased dopamine uptake in striatal synaptosomes after treatment of rats with amantadine

European Journal of Pharmacology

Volumn 403, Issue 1-2, 2000, Pages 75-80

  Page, Guylène ^a   Peeters, Magali ^a   Maloteaux, Jean Marie ^a   Hermans, Emmanuel ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Dopamine uptake; Glutamate; NMDA receptor; Parkinson's disease

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; AMANTADINE; DOPAMINE TRANSPORTER; DYNATRA 200; GLUTAMATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EXPOSURE; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR AFFINITY;

AMANTADINE; ANIMALS; BINDING, COMPETITIVE; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PIPERAZINES; RATS; RATS, WISTAR; SYNAPTOSOMES; TRITIUM;

EID: 0034284085     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00573-2     Document Type: Article

References (39)

1. Baldessarini R.J., Lipinski J.F., Chace K.V. Effects of amantadine hydrochloride on catecholamine metabolism in the brain of the rat. Biochem. Pharmacol. 21:1972;77.
2. Batchelor M., Schenk J.O. Protein kinase A activity may kinetically upregulate the striatal transporter for dopamine. J. Neurosci. 18:1998;10304-10309.
3. 3H]-GBR 12783 specific binding during the maturation of rat striatum. Life Sci. 44:1989;1759-1765.
4. Brown F., Redfern P.H. Studies on the mechanism of action of amantadine. Br. J. Pharmacol. 58:1976;561-567.
5. 2 dopamine receptors can modulate dopamine uptake. Neurosci. Lett. 176:1994;259-263.
6. Cepeda C., Levine M.S. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev. Neurosci. 20:1998;1-18.
7. Danysz W., Gossel M., Zajaczkowski W., Dill D., Quack G. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? - Case of amantadine and memantine. J. Neural. Transm. 7:1994;155-166.
8. 2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum. J. Neurochem. 72:1999;148-156.
9. Farnebo L-O., Fuxe K., Goldstein M., Hamberger B., Ungerstedt U. Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinson's disease. Eur. J. Pharmacol. 16:1971;27-38.
10. Fisher A., Biggs C.S., Starr M.S. Differential effects of NMDA and non-NMDA antagonists on the activity of aromatic L-amino acid decarboxylase activity in the nigrostriatal dopamine pathway of the rat. Brain Res. 792:1998;126-132.
11. Fletcher E.A., Redfern P.H. The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates. J. Pharm. Pharmacol. 22:1970;957-958.
12. Gianutsos G., Chute S., Dunn J.P. Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur. J. Pharmacol. 110:1985;357-361.
13. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
14. Glowinski J., Iversen L.L. Regional studies of catecholamines in rat brain. J. Neurochem. 13:1966;655-663.
15. Gordon I., Weizman R., Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur. J. Pharmacol. 298:1996;27-30.
16. 3-dopamine in rat brain slices. Eur. J. Pharmacol. 20:1972;156-160.
17. Heimans R.L., Rand M.J., Fennessy M.R. Effects of amantadine on uptake and release of dopamine by a particulate fraction of rat basal ganglia. J. Pharm. Pharmacol. 24:1972;875-879.
18. Herblin W.F. Amantadine and catecholamine uptake. Biochem. Pharmacol. 21:1972;1993-1995.
19. 3H]GBR-12935 binding in brain: a radioligand for selective labelling of the dopamine transport complex. J. Neurochem. 46:1986;1272-1276.
20. 3H-PCP binding. Pharmacol. Biochem. Behav. 22:1985;731-735.
21. Kornhuber J., Weller M. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol. Psychiatry. 41:1997;135-144.
22. Kornhuber J., Weller M., Schoppmeyer K., Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J. Neural. Transm. 43:1994;91-104.
23. Kornhuber J., Quack G., Danysz W., Jellinger K., Danielczyk W., Gsell W., Riederer P. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology. 34:1995;713-721.
24. Lang A.E., Blair R.D.G Anticholinergic drugs and amantadine in the treatment of Parkinson's disease. Calne D.B. Drugs for the Treatment of Parkinson's Disease. 1989;307-323 Springer-Verlag, New York.
25. 2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J. Neurochem. 61:1993;764-767.
26. Mizoguchi K., Yokoo H., Yoshida M., Tanaka T., Tanaka M. Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism. Brain Res. 662:1994;255-258.
27. Nishimura M., Sato K. Ketamine stereoselectively inhibits rat dopamine transporter. Neurosci. Lett. 274:1999;131-134.
28. Nishimura M., Sato K., Okada T., Schloss P., Shimada S., Tohyama M. MK-801 blocks monoamine transporters expressed in HEK cells. FEBS Lett. 423:1998;376-380.
29. Peterson G.L. A simplification of the protein assay method of Lowry et al. Which is more generally applicable. Anal. Biochem. 83:1977;346-356.
30. Porter R.H.P., Greenamyre J.T. Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J. Neurochem. 64:1995;614-623.
31. Pristupa Z.B., McConkey F., Liu F., Man H.Y., Lee F.J.S., Wang Y.T., Niznik H.B. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse. 30:1998;79-87.
32. Quirion R., Pert C.B. Amantadine modulates phencyclidine binding site sensitivity in rat brain. Experientia. 38:1982;955-956.
33. Scatton B., Cheramy A., Besson M.J., Glowinski J. Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur. J. Pharmacol. 13:1970;131-133.
34. Schwab R.S., England A.C., Poskanzer D.C., Young R.R. Amantadine in the treatment of Parkinson's disease. JAMA. 208:1969;1168-1170.
35. Snell L.D., Johnson K.M. Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur. J. Pharmacol. 145:1988;223-226.
36. Sonders M.S., Zhu S-J., Zahniser N.R., Kavanaugh M.P., Amara S.G. Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J. Neurosci. 17:1997;960-974.
37. Takahashi T., Yamashita H., Zhang Y-X., Nakamura S. Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res. Bull. 41:1996;363-367.
38. Uitti R.J., Rajput A.H., Ahlskog J.E., Offord K.P., Schroeder D.R., Ho M.M., Prasad M., Rajput A., Basran P. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology. 46:1996;1551-1556.
39. Vaughan R.A. Regulation of dopamine transporter by phosphorylation and impact on cocaine action. Reith M.E.A. Cerebral Signal Transduction: From First To Fourth Messengers. 2000;374-399 Humana Press, Totowa, NJ.